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AbstrAct:
AXL is a receptor tyrosine kinase of the TAM family, the function of which is poorly 
understood. We previously identified AXL overexpression in Imatinib (IM)-resistant 
CML cell lines and patients. The present study was conducted to investigate the 
role of AXL and the mechanisms underlying AXL overexpression in Tyrosine Kinase 
Inhibitor (TKI)-resistant CML cells. We present evidence that high AXL expression 
level is a feature of TKI-resistant CML cells and knockdown of AXL sensitized TKI-
resistant cells to IM. In addition, expression of wild-type AXL but not a dominant 
negative form of AXL confers IM-sensitive CML cells the capacity to resist IM effect. 
AXL  overexpression  required  PKCα  and  β  and  constitutive  activation  of  ERK1/2. 
Accordingly,  GF109203X  a  PKC  inhibitor,  U0126  a  MEK1  inhibitor  and  PKCα/β 
knockdown restore sensitivity to IM while PKCα or PKCβ overexpression in CML cells 
promotes protection against IM-induced cell death. Finally, using luciferase promoter 
activity assays we established that AXL is regulated transcriptionally through the 
AP1 transcription factor. Our findings reveal an unexpected role of AXL in resistance 
to TKI in CML cells, identify the molecular mechanisms involved in its overexpression 
and support the notion that AXL is a new marker of resistance to TKI in CML.
IntroductIon
A feature of chronic myeloid leukemia (CML) cells 
is the presence of the Philadelphia chromosome (Ph) that 
results from the t(9;22)(q34;q11) translocation [1]. The 
Ph gene encodes BCR-ABL, an oncogenic fusion protein. 
In CML, p210-BCR-ABL is a constitutively activated 
tyrosine kinase that triggers several signaling pathways 
which collectively confers CML cells a proliferative 
advantage and resistance to apoptosis [2-5]. Imatinib 
(IM), a tyrosine kinase inhibitor (TKI) is used frequently 
as  the  first  line  treatment  for  patients  suffering  CML 
[6, 7], even though other TKIs including Dasatinib and 
Nilotinib are now also given as a first line therapy in CML 
patients. Nevertheless, resistance to TKI which occurs 
in all phases of the disease [8] represents a recurrent 
problem for CML patients. Importantly, activation of 
tyrosine kinases including LYN, FYN, and AXL has been 
reported in IM and Nilotinib-resistant cell lines and also 
in some CML patients treated with such inhibitors [9-11]. 
Therefore, targeting tyrosine kinases, expression of which 
is elevated in resistant patients could be a pertinent option 
to treat TKI-refractory patients. 
We have shown previously that AXL is overexpressed 
in CML cell lines resistant to IM and PD166326, a dual 
BCR-ABL and SRC kinase inhibitor of the Dasatinib 
family. AXL is a member of the TAM family of receptor Oncotarget 2011; 2:  874 - 885 875 www.impactjournals.com/oncotarget
tyrosine kinase (RTK) initially isolated from primary 
human myeloid leukemia cells [12]. The TAM receptor 
family also includes the Tyro-3 and Mer receptors which 
share with AXL subsequent sequence homologies [13]. 
AXL overexpression is a common feature of cancer cells. 
Moreover, increased AXL level and activation have been 
linked with Imatinib resistance in gastrointestinal stromal 
tumors (GIST) [14], Nilotinib resistance in CML cells 
[11], resistance to BMS-754087 in Rhabdomyosarcoma 
[15], Lapatinib resistance in HER-2 positive breast tumor 
cells [16] and in Cisplatin-resistant ovarian cancer [17]. 
AXL has been also shown to be induced by chemotherapy 
drugs in acute myeloid leukemia [18] and AXL is 
consistently associated to drug-mediated resistance in 
several types of cancer [15, 16, 18, 19]. Although, it seems 
well established that AXL is involved in resistance to 
chemotherapy in cancer cells, the mechanisms underlying 
AXL overexpression in this context remain unexplored. 
In the present study, we report compelling evidence 
that AXL is overexpressed in several TKI-resistant CML 
cell lines. Importantly, we establish that AXL knockdown 
using specific siRNA sensitized TKI-resistant cells to IM 
effect. Moreover, overexpression of AXL-WT but not 
AXL-DN which lacks the kinase domain allowed IM-
sensitive CML cells to resist IM treatment. Importantly, 
we also bring evidence that PKCα and β and constitutive 
activation of the ERK1/2 pathway are required for 
AXL overexpression in TKI-resistant cells lines. 
Accordingly, pharmacological inhibition of classical 
PKC and MEK1 or PKCα/β silencing by specific siRNA 
restores sensitivity to Imatinib while PKCα and PKCβ 
overexpression or PMA treatment in TKI-sensitive cells 
confers protection against Imatinib-induced cell death. In 
addition, luciferase promoter activity assays also indicate 
that AXL overexpression is regulated at the transcriptional 
level by the AP1 transcription factor in TKI-resistant 
cells.  Collectively,  our  findings  demonstrate  the  role 
of AXL in resistance to TKI in CML cells and identify 
the involvement of PKC and ERK1/2 pathways in AXL 
accumulation. Our data support the notion that AXL could 
be a pertinent prognostic marker for resistance to TKI in 
CML cells.
results
AXl overexpression protects IM-r and Pd-r 
cells against IM effects
We have previously reported that AXL is 
overexpressed in IM-resistant CML cell lines [9, 20]. This 
was confirmed in K562 cells resistant to the dual SRC/
BCR-ABL inhibitor PD166326 (PD-R) cells (Figure 
1A). AXL was present in both the cytoplasmic and 
microsomal fractions of TKI-resistant cell lines, but was 
absent from the nuclear fraction (Figure 1B). To assess 
the level of phosphorylation of AXL, we performed 
immuno-precipitation assays from IM-S, IM-R and 
PD-R CML cells followed by western blot with the 
specific 4G10 anti-phosphotyrosine monoclonal antibody 
(Figure 1C). As expected, AXL phosphorylation, which 
reflected  AXL  activity,  was  found  only  in  IM-R  and 
PD-R resistant cell lines. To investigate the role of AXL 
overexpression in resistance to TKI in K562 CML cells 
we used a siRNA approach. A siRNA directed against 
AXL efficiently inhibited AXL expression in both IM-R 
and PD-R CML cells (Figure 1D, bottom panel). AXL 
knockdown by itself had no effect on cell metabolism 
but sensitized drastically IM-R and PD-R cells to IM-
mediated loss of cell metabolism (Figure 1D, top panel) 
and also decreased total cell counts (Sup Figure 1A). As 
expected, IM abolished the clonogenic potential of IM-S 
cells but had minimal effect on IM-R and PD-R CML 
cells (Figure 1E). Knockdown of AXL by itself failed 
to affect the clonogenic potential of IM-R and PD-R but 
strongly reduced the number of colonies when combined 
with IM. Indeed, quantitative analysis of colonies counts 
by the Image J software revealed a 80% decrease in the 
number of IM-R and PD-R colonies in the presence of 
the combination of the AXL siRNA and IM versus only 
25% with IM alone (Figure 1F). Knockdown of AXL also 
sensitized IM-R and PD-R cells to the effect of PD166326 
(Sup Figure 1B). By contrast, AXL knockdown did not 
modify the effect of staurosporine on cell metabolism 
linking specifically AXL expression to IM resistance (Sup 
Figure 1C).
Knockdown of AXl induces apoptosis of tKI-
resistant cMl cell lines
To determine whether loss of cell metabolism and 
clonogenic potential reflected increased cell death, IM-S, 
IM-R and PD-R CML cell lines were treated or not with IM 
in the presence or the absence of a siRNA directed against 
AXL. As expected IM increased the number of dead cells 
from 8 to 28% but had no effect on both IM-R and PD-R 
cells (Figure 2A). AXL knockdown restored sensitivity to 
IM in both IM-R and PD-R cells to almost the same level 
than in control cells (26 and 22% dead cells respectively 
versus 33% in IM-S cells). Accordingly, AXL knockdown 
specifically increased caspase 3 and 9 activities and Poly-
ADP-Ribose-Polymerase cleavage (Figures 2B, C and 
D). To verify that the observed effects were not due to 
clonal variations, we also analyzed the IM-resistant cell 
line JURLMK1-R. Resistance of JURLMK1-R to IM 
was also correlated with overexpression of AXL (Sup 
Figure 2A). Identical results were obtained regarding cell 
metabolism when JURLMK1-R CML cells were assessed 
for annexin V/PI staining and caspase 3 activity (Sup 
Figures 2B, C and D). All together our findings show that 
increased cell death is one the main mechanisms by which Oncotarget 2011; 2:  874 - 885 876 www.impactjournals.com/oncotarget
the AXL siRNA exerted its effect. Moreover, our data also 
highlight that AXL overexpression and/or activity could 
represent a hallmark of resistance to TKI in CML (8, 11). 
Finally, the importance of caspases in the pro-apoptotic 
effect of the AXL siRNA was confirmed using the pan 
caspase inhibitor z-VAD-fmk which was found to block 
the effect of AXL silencing on both cell metabolism and 
caspase 3 activation (Sup Figure 3A and B).
characterization of the mechanisms involved in 
AXl overexpression 
To investigate the possible mechanisms involved 
in AXL overexpression in IM-R and PD-R cells we first 
used a pharmacological approach. Among the different 
compounds used, only GF109203X (GFX), an inhibitor  Figure 1                        Dufies and al.
A. B.
AXL
HSP60
IM‐S  IM‐R   PD‐R
E.
C.
D.
0
20
40
60
80
100
120
C
e
l
l
 
m
e
t
a
b
o
l
i
s
m
 
(
%
)
Ima ‐ +
IM‐S
IM‐R
PD‐R
AXL
P‐Tyr IP AXL
IP AXL
AXL 
IM‐S  IM‐R  PD‐R
Total
Ima ‐ +           ‐ + 
siAXL ‐‐ +           + 
0
20
40
60
80
100
120
C
l
o
n
o
g
e
n
i
c
c
e
l
l
(
%
) IM‐S
IM‐R
PD‐R
IM‐S             IM‐R              PD‐R
siCT
siCT
+ Ima
siAXL
siAXL
+ Ima
1    2    3     1    2    3    1    2    3 
IM‐S            IM‐R          PD‐R 
AXL
HSP60
Tubulin
1: cytoplasmic, 2: microsomal, 3: nuclear
siAXL ‐‐ +   +   ‐ ‐ +   +   ‐ ‐ +   +
Ima ‐ + ‐ +   ‐ + ‐ +   ‐ +   ‐ +     
IM‐S              IM‐R               PD‐R
AXL
HSP60
0
20
40
60
80
100
120
C
e
l
l
 
m
e
t
a
b
o
l
i
s
m
 
(
%
)
Ima ‐ +          ‐ + 
siAXL ‐‐ +          + 
IM‐S
IM‐R
PD‐R
F.
Figure 1: AXl is overexpressed in tKI-resistant cMl cell lines and protects them against tKI-induced apoptosis. 
(A) IM-S, IM-R and PD-R cells were incubated for 48h with 1µM IM. Cell metabolism was measured using the XTT assay (top panel). 
Protein extracts were prepared, and 50µg of proteins was subjected to SDS-PAGE followed by immunoblot analysis (bottom panel). (B) 
Cell extracts were separated into cytosol, mitochondria and nuclear-enriched fractions and AXL location was assessed by Western blot 
in the different fractions. HSP60 and tubulin served as both loading control and validation of the membrane and cytoplasmic fractions, 
respectively. (C) Cell extracts were prepared and AXL was immuno-precipitated with an anti-AXL antibody. AXL phosphorylation was 
analyzed by western blot using the 4G10 anti-phosphotyrosine antibody. (D) Cells were transfected with control or AXL siRNAs. 48h 
after transfection, cells were treated with IM (1µM) for 48h. Cell metabolism was measured using the XTT assay and AXL expression was 
analyzed by Western blot. (E and F) Cells were transfected with control or AXL siRNAs. After 48h, IM (1µM) was added to cell lines 
growing in semi-solid methylcellulose medium (E). (F) Results are expressed as the percentage of colony forming cells after drug treatment 
in comparison with the untreated control cells. Oncotarget 2011; 2:  874 - 885 877 www.impactjournals.com/oncotarget
of classical and new PKCs, and U0126, a MEK1 inhibitor, 
dampened AXL expression in IM-R and PD-R CML cell 
lines (data not shown). Therefore both PKC and MEK/
ERK pathways are involved in AXL overexpression in 
TKI-resistant CML cell lines. If GFX was capable to inhibit 
AXL expression levels in IM-R and PD-R CML cells, it 
should sensitize these cells to IM effect. Although GFX 
by itself induced only a limited loss of cell metabolism in 
TKI-resistant cells, it synergized with IM to promote loss 
of cell metabolism in IM-R and PD-R cells (Sup Figure 
4A and B). Accordingly, GFX also sensitized IM-R and 
PD-R CML cells to IM-induced apoptosis as judged by 
increased annexin V staining (Sup Figure 4C) and caspase 
3 activity (Sup Figure 4D).
PKCα and β are responsible for increased AXL 
expression in resistant cMl cells
As GFX drastically inhibits AXL expression in both 
IM-R and PD-R cells, we postulated that classical and/
or new PKC isoforms could be responsible for increased 
expression of this RTK. We have reported previously that 
PKCα and β are strongly expressed in K562 cells [21, 22]. 
Importantly, abrogation of both PKCα and β expression by 
a dual PKCα/β siRNA results in a parallel decrease of AXL 
expression, irrespectively of the presence or the absence of 
IM (Figure 3A). Knockdown of PKCα/β was accompanied 
by a sensitization to IM treatment in accordance with the 
effect of pharmacological inhibition of PKCs (Figure 3B 
and Sup Figure 5B). Importantly, silencing of both PKCα 
and β led to an increase in Annexin V staining (Figure 3C) 
and caspase 3 activity (Figure 3D) only in TKI-resistant 
cells treated with Imatinib. In addition, overexpression of 
PKCα or β induced AXL expression in IM-S K562 cells, 
while co-expression of both isoforms triggered further 
AXL accumulation (Figure 4A). PKCα and β were also 
shown to protect IM-S cells from IM-mediated loss of 
cell metabolism (Figure 4B) and apoptosis as judged by 
AnnexinV/PI staining (Figure 4C) and caspase 3 activity 
(Figure 4D), even though co-transfection of both isoforms 
conferred further protection.
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Figure 2                        Dufies and al.
Figure 2: AXl extinction sensitizes tKI-resistant cMl cells to IM. Cells were transfected with control or AXL siRNA. 48h 
after siRNA transfection cells were treated with IM (1µM) for 48h. (A) Cells were stained with the PI/ annexin-V-fluos staining kit 
according to the manufacturer’s indications. Histograms show both annexin-V+/PI- cells (open bars) and annexin-V+/PI+ cells (filled bars). 
(B, C) Cells were lysed in caspase buffer and caspase-3 (B) and -9 activities (C) were evaluated in quadruplicate using 0.2mM Ac-DEVD-
AMC or Ac-LEDH-AMC as substrates. Results expressed as arbitrary units (A.U.) /mg of protein.min and are means ± Standard deviation 
of 4 independent experiments made in quadruplicate. Error bars 95% confidence intervals. (D) AXL expression and cleavage of PARP was 
analyzed by Western blot. Oncotarget 2011; 2:  874 - 885 878 www.impactjournals.com/oncotarget
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Figure 3: Inhibition of PKCα/β signaling sensitizes TKI-resistant cells to IM-induced apoptosis. Cells were transfected 
with control siRNA or a dual PKCα/β siRNA. 48h after siRNA transfection cells were treated with IM (1µM) for 48 h. (A) PKCα, β and 
γ expression was analyzed by western blot. (B) Cell metabolism was measured using the XTT assay. (C) Cells were stained with the PI/
annexin-V-fluos staining kit and analyzed as described in Fig 2A. (D) Caspase 3 activity was assessed as described in Fig 2B.
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Figure 4: Overexpression of PKCα/β in IM-S CML cells confers protection against apoptosis. PKCα and/or PKCβ plasmids 
were transfected in IM-S cells. 48h after transfection cells were treated with IM (1 µM) for 48 h. (A) AXL, PKCα or β expression was 
analyzed by western blot. (B) Cell metabolism was measured using the XTT assay. (C) Cells were stained with the PI/annexin-V-fluos 
staining kit as described in Fig 2A. (D) Caspase 3 activity was assessed as described in Fig 2B. Oncotarget 2011; 2:  874 - 885 879 www.impactjournals.com/oncotarget
overexpression of AXl-Wt or AXl-dn 
differently affects IM-mediated apoptosis
As previously mentioned, PKCα and β can protect 
cells from IM-induced cell death by different mechanisms 
including AXL overexpression. To assess the implication 
of AXL in CML cell protection, we next overexpressed 
a wild-type (AXL-WT) or a kinase deleted mutant of 
AXL (AXL-DN) in IM-S K562 cells. We first checked 
expression and phosphorylation of AXL in transfected 
cells. As shown on Figure 5 A, both forms of AXL protein 
were present at a similar level in IM-S cells, but tyrosine 
phosphorylation of AXL was detected only in cells 
transfected with the wild-type construct. Importantly, 
AXL-WT but not AXL-DN over-expression conferred 
IM-S cells protection against IM-induced loss of cell 
metabolism (Figure 5B), apoptosis as judged by Annexin 
V/PI staining (Figure 5C) and caspase 3 activity (Figure 
5D). Importantly, no protective effect was observed with 
AXL-DN indicating that the protective effect of AXL was 
strictly dependent on its kinase activity. The protection 
triggered by AXL overexpression although not complete 
was equivalent to the one induced by PKCα or β (Figure 
4) suggesting that AXL is one if not the main cause of 
resistance to IM in IM-R and PD-R CML cell lines. 
When the same experiments were reproduced in IM-R 
cells, increased level of AXL-WT and AXL-DN were 
detected (Figure 5E). Overexpression of AXL-WT in 
IM-R cells failed to alter cell metabolism, whereas AXL-
DN inhibited drastically cell metabolism in the presence 
of IM (Figure 5F). This was also correlated with increased 
cell death as assessed by Annexin V/PI staining (Figure 
5G) and caspase 3 assay (Figure 5H).
Role of ERK1/2 activation in AXL overexpression
We reported earlier that ERK1/2 is constitutively 
activated in IM-R CML cells [20]. Accordingly, AXL 
overexpression correlated also with persistent activation 
of ERK1/2 in IM-R and PD-R CML cells (Figure 6A). 
Interestingly, inhibition of ERK1/2 by the MEK1 inhibitor 
U0126 abolished AXL expression (Figure 6A). In addition 
U0126  also  sensitized  TKI-resistant  CML  cells  to  IM 
(Figure 6B). Finally, U0126 increased both IM-induced 
annexin V/PI staining (Figure 6C) and caspase 3 activity 
(Figure 6D) in IM-R and PD-R CML cell lines. Taken 
together our data established that ERK1/2 is required for 
AXL expression upstream of PKCα and β in TKI-resistant 
CML cell lines. In addition, Figure 6E showed that IM-
S, IM-R and PD-R cell lines expressed the same level of 
PKCα and β expression and phosphorylation. Importantly, 
U0126  significantly  inhibited  expression  of  PKCα  and 
β in IM-R and PD-R cells but not in their IM-sensitive 
counterpart. Translocation rather than global expression of 
both PKC isoforms was impaired in IM-R cells as judged 
by subcellular fractionation (Figure 6F). Collectively, our 
findings support the notion that in IM-resistant CML cells 
constitutive activation of the ERK pathway is responsible 
for PKCα and β activation.
AP1 is required for AXl overexpression in tKI-
resistant cMl cells
To get insights into the mechanisms of AXL 
regulation in CML cells we performed luciferase activity 
assays using a minimal AXL promoter carrying or not a 
mutation on its AP1 binding site. Promoter activity was 
8 and 6 times higher in IM-R and PD-R cells respectively 
compared  to  control  cells,  reflecting  increased  AXL 
transcription in these cell lines (Figure 7A). When using 
the mutated promoter there was an 80% decrease in 
luciferase activity arguing for an important role of AP1 
in AXL overexpression. AXL transcription was abolished 
by U0126 highlighting the role of ERK1/2 in this process 
(Figure  7B). Accordingly,  knockdown  of  PKCα/β  was 
associated with a drastic inhibition of AXL transcription 
in IM-R and PD-R CML cells (Figure 7C). Finally, 
overexpression of PKCα or PKCβ triggered activation of 
the AXL promoter, the combination of both being more 
efficient that the individual expression of one of these 
isoforms (Figure 7D). Finally, it is worth noting that the 
level of activation of the AXL promoter was identical 
whatever the situation in TKI-resistant cells and IM-S 
cells transfected with the combination of PKCα and β, 
highlighting the role of PKCs in the regulation of AXL.
dIscussIon
We report here that over-expression of the RTK 
AXL is consistently detected in several TKI-resistant 
CML cell lines and that silencing of AXL with specific 
siRNA sensitizes TKI-resistant cells to IM-mediated loss 
of cell viability and apoptosis. We also bring evidence that 
a WT, but not a dominant-negative AXL protein lacking 
the kinase domain, confers IM-sensitive cells the capacity 
to resist IM treatment. Pharmacological inhibition of 
classical PKC and MEK1 or PKCα/β silencing by specific 
siRNA restores sensitivity to IM while PKCα and PKCβ 
overexpression in TKI-sensitive cells confers protection 
against IM-induced cell death demonstrating that both 
PKCα and β and constitutive activation of ERK1/2 are 
required for AXL overexpression. In addition, we show 
that AXL overexpression is regulated at the transcriptional 
level by the AP1 transcription factor in TKI-resistant cells.
Increased expression of AXl is involved in 
resistance to tKI
Increased expression of AXL is a recurrent 
characteristic of cancer cells. AXL overexpression Oncotarget 2011; 2:  874 - 885 880 www.impactjournals.com/oncotarget
and/or activation has been linked with resistance to 
chemotherapy in gastrointestinal stromal tumor cell lines 
[14], in CML cells [11], rhabdomyosarcoma [15], HER-
2 positive breast tumor cells [16] and ovarian cancer 
[17]. In addition, AXL has been shown to be induced 
by chemotherapy drugs in acute myeloid leukemia [18]. 
Accordingly, a recent study has reported that inhibition 
of AXL expression in Nilotinib-resistant CML cells lines 
can restore sensitivity to Nilotinib [11]. Indeed, Gioia et 
al. showed that AXL interacts with both Syk and Lyn to 
mediate resistance to Nilotinib in the K562 CML cell line. 
Interestingly, these Nilotinib-resistant CML cells were 
shown to display constitutive activation of Lyn a situation 
that is closed to the one observed in our TKI-resistant 
K562 cell lines where the Fyn but not Lyn tyrosine 
kinase is constitutively activated and participates to 
persistent ERK1/2 activation [9, 10, 20]. Therefore, AXL 
activation in TKI-resistant CML cells could be achieved 
by two different but complementary pathways, increased 
signaling or increased protein expression, both leading to 
resistance to TKIs. It has been reported that dominant-
negative inhibition of AXL suppresses brain tumor growth 
and invasion and prolongs survival in a mice model of 
gliomagenesis [23]. This was the first direct proof that the 
tyrosine kinase activity of AXL can be involved in tumor 
progression. Accordingly, we established here using AXL-
DN constructs that AXL activity is necessary to confer 
resistance to IM-sensitive cells. 
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Figure 5: over-expression of AXl renders IM-s cells resistant to IM. AXL-WT or AXL-DN plasmids were transfected in IM-S 
(A-D) or IM-R cells (E-H), respectively. 48 h after transfection, cells were treated with IM (1µM) for 48h. (A and E), cells were lysed, 
immuno-precipitated with an AXL antibody and phosphorylation of AXL analyzed by Western blot using a phospho-tyrosine antibody 
(4G10).  (B and F) Cell metabolism was measured using the XTT assay. (C and G) Cells were stained with the PI/annexin-V-fluos staining 
kit for evaluation of dead and apoptotic cells. (D and H) Caspase 3 activity was assessed as described in Fig 2. Oncotarget 2011; 2:  874 - 885 881 www.impactjournals.com/oncotarget
regulation of AXl expression in tKI resistant 
cell lines
It is well established that AXL stimulated cell 
proliferation through the MAPK/ERK and PI3K/AKT 
pathways [19, 24-26]. As mentioned before, we have 
shown previously that IM-R and PD-R CML cells 
exhibited persistent activation of a Fyn/ERK module 
that participates to TKI-resistance [20]. However, 
overexpression of AXL in TKI-resistant cells is not 
responsible for increased ERK activity since knockdown 
of AXL using specific siRNA failed to inhibit constitutive 
ERK activation in IM-R and PD-R cells (data not shown). 
Caveat to that, AXL overexpression is dependent on 
persistent ERK activation since inhibition of ERK by 
U0126 blocked AXL transcription and expression in IM-R 
and PD-R CML cells leading to increased apoptosis and 
caspase activation. Besides ERK, we bring for the first 
time evidence that PKCα and β are also involved in AXL 
overexpression. This observation is in good agreement 
with the fact that AXL has been identified initially as a 
gene induced by phorbol esters in CML cells [21, 27, 28]. 
AXl expression is regulated at the transcriptional 
level in resistant cMl cells
The mechanisms governing AXL expression are 
poorly understood. However, in a recent study, it has 
been reported that PMA-mediated increased in AXL is 
regulated at the transcriptional level essentially through 
the AP1 transcription factor [27]. Accordingly, using 
luciferase assays, we established that PKCα and β were 
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Figure 6: U0126 sensitizes TKI-resistant CML cell lines to IM via inhibition of PKCα and β translocation. (A-D) Cells 
were treated with U0126 (10µM). 48h after, cells were treated with Imatinib (1µM) for 48h. (A) AXL, ERK expression and Phospho-ERK 
status were analyzed by Western blot. (B) Cell metabolism was measured using the XTT assay. (C) Cells were stained with the PI/annexin-
V-fluos staining kit and analyzed as described in Figure 2A. (D) Caspase 3 activity was assessed as described in Fig 2B. (E-F) Cells were 
treated with U0126 (10µM) for 4h. (E) PKCα, PKCβ expression and Phospho-PKCα/β status were analyzed by Western blot. (F) Cell 
extracts were separated into cytosol and membrane fractions and PKCα, PKCβ and Phospho-PKCα/β location was assessed by Western blot 
in the different fractions. Lamp2 served as loading control and validation of the microsomal fraction.Oncotarget 2011; 2:  874 - 885 882 www.impactjournals.com/oncotarget
required for increased transcription of AXL in IM-R cells. 
Importantly, pharmacological and siRNA approaches 
allowed us to determine that increased transcription and 
expression of AXL in TKI-resistant cells are dependent 
on both ERK and PKCα and β signaling. One important 
question that remains to be answered is whether ERK1/2 
and PKC act independently to promote AXL accumulation 
in TKI-resistant or whether it exist a hierarchy of 
activation of these kinase pathways. Importantly, we 
established the hierarchy of kinase activation leading to 
AXL overexpression. Indeed, we showed that ERK1/2 
is involved upstream of PKCα and β to regulate AXL 
expression in TKI-resistant CML cells since inhibition of 
MEK1 by U0126 abrogated PKCα and β translocation and 
as consequence on AXL expression only in IM-resistant 
cells.  Collectively  our  finding  supports  the  notion  that 
the constitutive activation of ERK in TKI-resistant cells 
control translocation and activity of PKCα and β which in 
turn are involved in increased transcription and expression 
of AXL.
targeting AXl in tKI-resistant cMl cell lines
Findings from other and our present data clearly 
indicate that increased expression of AXL is a common 
feature of cancer cells [26, 29-32]. This seems particularly 
true regarding CML and AML. Moreover, increased 
expression of AXL is often associated to chemotherapy 
drug resistance [15, 16, 18, 19]. Therefore, targeting AXL 
could represent a promising strategy for TKI-resistant 
patients. Until now, no specific inhibitors of AXL have 
been  characterized.  MP470  is  reported  to  inhibit AXL 
in vitro and in vivo [14] but is also effective at identical 
concentrations on other RTKs [33, 34]. For instance, 
MP470 was found effective to sensitize the IM-resistant 
GIST882 cell line to IM, but it is not known from the 
results of this study whether this effect is due to effective 
AXL inhibition. In this line, we have shown that MP470 
efficiently killed IM-R K562 cells. However, MP470 was 
found to affect IM-S K562 cell as well, strongly suggesting 
that at least in the case of CML, AXL is not an MP470 
target. In the absence of highly specific AXL inhibitor the 
use of siRNA directed against AXL have however brought 
clear evidence that AXL is involved in TKI-resistance. 
The  development  of  highly  specific  inhibitors  of AXL 
will certainly help deciphering further the role of this 
RTK in resistance to TKI and to propose new therapeutic 
strategies in hematopoietic malignancies [35].
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Figure 7: transcriptional regulation of AXl in tKI-resistant cMl cells. Cells were transfected with luciferase reporter 
plasmids (pAXL-WT or pAXL-DN muted). (A) 24h after transfection, cells were lysed and luciferase activity was measured to determine 
AXL promoter activity. (B, D) 24 h after transfection, cells were treated with 10µM U0126 for 24h (B). Cells were then lysed and luciferase 
activity was measured. (C, D) 24 h after transfection, cells were transfected with a dual PKC α/β siRNA (C) or with PKC α or/and PKC β 
plasmid (D) for 24h. Cells were then lysed and luciferase activity measured. (A to E) Results are expressed as arbitrary units (A.U.) / mg 
of protein. min and are means ± standard deviation of 3 independent experiments made in triplicate. Error bars 95% confidence intervals.Oncotarget 2011; 2:  874 - 885 883 www.impactjournals.com/oncotarget
MAterIAls And Methods
Reagents and antibodies:
Imatinib mesylate (STI571, Gleevec) was purchased 
from Enzo Life Sciences (Farmingdale, NY, USA) and 
RPMI 1640 medium, IMDM medium and fetal calf 
serum (FCS) from life technologies (Carlsbad, CA, 
USA). Sodium fluoride, sodium orthovanadate, phenyl-
methyl-sulfonyl  fluoride  (PMSF),  aprotinin,  leupeptin 
and Phorbol-12-Myristate-13-Acetate (PMA) were 
purchased from Sigma-Aldrich (France). Ac-DEVD-
7-amino-4-methylcoumarin (AMC), Ac-LEHD-AMC, 
Ac-DEVD-CHO,  Ac-LEHD-CHO  and  zVAD-fmk 
were from peptanova (PeptaNova GmbH, Sandhausen, 
Germany). Anti-HSP90, anti-HSP60, anti-tubulin and 
anti-AXL  antibodies  were  purchased  from  Santa  Cruz 
Biotechnology (Santa Cruz, CA, USA). HRP conjugated 
anti-mouse and anti-goat antibodies were from Dakopatts 
(Glostrup, Denmark). Anti-phosphotyrosine (P-Tyr), anti-
PARP, anti-PKCα, anti-PKCβ, anti-PKCγ, anti-phospho-
ERK, and peroxydase-conjugated anti-rabbit antibodies 
were purchased from Cell Signaling Technology (Beverly, 
MA, USA). Staurosporine, U0126, SP600125, SU6656, 
GF109203X, PP2 and SB202474 were from Calbiochem 
(San Diego, USA). 
rnA interference:
AXL (UCGCGGUGCUGGGAGCUAA) and 
PKCα/β  (life  technologies)  specific  siRNAs  from  Life 
Technologies were transfected in cells using Lipofectamine 
RNAiMAX reagent as described previously [36].
Plasmids and luciferase reporter constructs: 
AXL-WT and AXL-DN (kinase-deleted) plasmids 
have been published elsewhere [23] and were kindly 
provided by Pr Axel Ullrich. PKCα and PKCβ have been 
described previously [22]. Luciferase reporter constructs 
of the AXL promoter were kindly provided by Dr Heile 
Allgayer. pAXL-WT represents the WT luciferase reporter 
construct (−1276/+7) and pAXL-AP1mut corresponds to 
luciferase reporter construct mutated into position (-637 
to -650 AP1 corresponding to the AP1 binding site) [27].
cell lines:
The human CML cells lines IM-S (K562) and 
JURLMK1 were grown at 37°C under 5% CO2 in RPMI 
supplemented with 5% FCS, 50 U/ml penicillin, 50 µg/ml 
streptomycin, and 1 mM sodium pyruvate. Establishment 
of resistant K562 cell clones (IM-R and PD-R) and 
resistant JURLMK1 cell clones (JURLMK1-R) have been 
described previously [9].
colony formation assay:
IM (1µM) was added to cells lines growing in 
semisolid methylcellulose medium (0.5x103  cells/ml; 
MethoCult H4236; StemCell Technologies Inc, Vancouver, 
BC, Canada). Colonies were detected after 10 days of 
culture  by  adding  1  mg/ml  of  3-(4,5-dimethylthiazol- 
2-yl)-2,5-diphenyltetrazolium  bromide  (MTT)  reagent 
and were scored by Image J quantification software (U.S. 
National Institutes of Health, Bethesda, MD, USA) [37].
caspase assays:
Caspase assays have been described in details 
elsewhere [4]. 
Flow cytometry:
Apoptosis analysis: After stimulation, cells were 
washed with ice-cold PBS and were stained with the 
annexin-V-fluos  staining  kit  (Roche,  Meylan,  France) 
according to the manufacturer’s procedure. Fluorescence 
was measured by using the FL2 channels of a fluorescence-
activated cell sorter apparatus (Miltenyi cytometer).
Western blot:
After stimulation, cells were harvested and lysed in 
buffer containing 1% Triton X-100 and supplemented with 
protease and phosphatase inhibitors (Roche Diagnostics). 
Lysates were pelleted, and 50 µg of protein were analyzed 
by SDS-PAGE as described previously [38]. 
Preparation of cytoplasmic, microsomal and 
nuclear fractions:
After stimulation, cells were washed and lysed as 
described previously [36]. Proteins contained in cytosolic, 
microsomal and nuclear fractions were separated by 
SDS-PAGE and transferred onto PVDF membrane before 
incubation with specific antibodies.
Cell viability (XTT):
Cells (15x103 cells/100 µl) were incubated in a 96-
well plate with different effectors for the times indicated 
in  the  figure  legends.  Fifty  microliters  of  sodium 
3’-[1-phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-
methoxy-6-nitro)  benzene  sulfonic  acid  hydrate  (XTT) Oncotarget 2011; 2:  874 - 885 884 www.impactjournals.com/oncotarget
reagent was added to each well. The assay is based on 
the cleavage of the yellow tetrazolium salt XTT to form 
an  orange  formazan  dye  by  metabolically  active  cells. 
The  absorbance  of  the  formazan  product,  reflecting 
cell viability, was measured at 490 nm. Each assay was 
performed in quadruplicate.
transfection and luciferase assays:
For luciferase assays, 106 cells were plated in 24-
well plates and cells were electroporated with the Amaxa 
Cell Line Nucleofector Kit V (Lonza, Switzerland) with 
1 µg of respective reporter plasmid and other plasmid. 
After 16 h of transfection, cells were treated with specific 
inhibitors for 24 h. Then, cells were lysed with 80 μl of 
lysis buffer (Promega, France) for 20 min. Luciferase 
activity of 20 μl of cell lysate was measured via the dual-
luciferase reporter assay system. 
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